Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | TGM2 | P21980 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 11/20 | 0.64 |
| ▸ | HINT1 | P49773 | 3/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.60 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.60 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL110999 | 0.93 | NT5E (0.65) | NT5ETGM2KRASHINT1TAS1R3 | |
| SCHEMBL112343 | 0.93 | NT5E (0.69) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL5356571 | 0.90 | NT5E (0.81) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL111255 | 0.88 | NT5E (0.66) | NT5ETGM2KRASHINT1TAS1R3 | |
| SCHEMBL109875 | 0.86 | POLB (0.67) | NT5ETGM2KRASTAS1R3TAS1R1 | |
| SCHEMBL29160869 | 0.84 | NT5E (0.77) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL14659957 | 0.84 | NT5E (0.77) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL18258303 | 0.84 | NT5E (0.77) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL9238744 | 0.84 | NT5E (0.80) | NT5ETGM2KRASHINT1IMPDH2 | |
| SCHEMBL12671484 | 0.84 | NT5E (0.80) | NT5ETGM2KRASHINT1IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | NT5E 253/4885TGM2 4080/4885KRAS 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.